GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences
GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March. More information about the presentations and panel discussions will be available on the Company’s website, under the Investors tab. Details are as follows:
GlycoMimtics，Inc.。納斯達克股票代碼：GERC)今天宣佈，該公司的高管計劃參加3月份的三個虛擬醫療會議。有關演講和小組討論的更多信息可在公司網站的投資者選項卡下獲得。詳情如下：
Cowen 41st Annual Health Care Conference
考恩第41屆衞生保健年會
March 1 – March 4, 2021
2021年3月1日-3月4日
Eric Feldman, M.D., GlycoMimetics Vice President, Clinical Development, to participate in Leukemias Panel
埃裏克·費爾德曼(Eric Feldman)，醫學博士，糖仿製學臨牀開發部副總裁，將參加白血病小組
Wed, March 3, 2021, 11:40 a.m. – 12:40 p.m. (EST)
星期三，2021年3月3日上午11：40-下午12：40(EST)
Access to the panel discussion is for registered attendees only.
只有已註冊的與會者才能參加小組討論。
H.C. Wainwright Global Life Sciences Conference
H.C.温賴特全球生命科學大會
March 9 – 10, 2021
2021年3月9日至10日
Rachel King, GlycoMimetics CEO, to present a corporate overview
GlycoMimtics首席執行官雷切爾·金介紹公司概況
The presentation will be available on-demand, beginning at 7 a.m. ET, March 9 through March 10. Access will be provided through the Company’s website (Investors section) and archived for 90 days.
演示文稿將於上午7點開始按需提供。美國東部時間3月9日至3月10日。訪問將通過公司網站(投資者部分)提供，並存檔90天。
33rd Annual Virtual Roth Conference
第33屆虛擬羅斯年會
March 15 – 17, 2021
2021年3月15日至17日
Rachel King, GlycoMimetics CEO, to present a corporate overview
GlycoMimtics首席執行官雷切爾·金介紹公司概況
Mon, March 15, 10:00 a.m. – 12:00 p.m. (EST) in Virtual 2 (Panel: Navigating Clinical Development in Rare Hematology & Inflammatory Disease). A link to the panel session will be available in the Investors section of the GlycoMimetics website.
星期一，3月15日，上午10：00-下午12點(EST)in Virtual 2(專題討論：導航罕見血液病和炎症性疾病的臨牀發展)。GlycoMimtics網站的投資者部分將提供小組會議的鏈接。
About GlycoMimetics, Inc.
關於GlycoMimtics公司
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy Designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com .
GlycoMimtics是一家生物技術公司，專注於血液腫瘤學和一系列新型仿糖藥物的流水線，所有這些藥物都是為了解決因碳水化合物生物學起關鍵作用的疾病而導致的未得到滿足的醫療需求。GlycoMimtics的候選藥物uproleselan是一種E-選擇素拮抗劑，在1/2期臨牀試驗中作為治療急性髓細胞白血病的潛在方法進行了評估，目前正在一系列患者中進行評估，其中包括公司贊助的突破性治療指定的復發/難治性急性髓細胞白血病的3期試驗。Rivipansel是一種泛選擇素拮抗劑，正在探索用於治療鐮狀細胞疾病的急性VOC。GlycoMimtics還完成了與另一種全資候選藥物GMI-1359的一期臨牀試驗，GMI-1359是一種CXCR4和E-選擇素聯合拮抗劑。GlycoMimtics公司位於馬里蘭州羅克維爾，位於生物健康首都地區。欲瞭解更多信息，請訪問www.garcomimetics.com。
譯文內容由第三人軟體翻譯。